Skip to content
Cancer Regulation and Immunology

Rautajoki lab

Publications

2025

  1. Hermelo, I, Virtanen, T, Salonen, I, Nätkin, R, Keitaanniemi, S, Tiihonen, AM et al.. Unsupervised clustering reveals noncanonical myeloid cell subsets in the brain tumor microenvironment. Cancer Immunol Immunother. 2025;74 (2):63. doi: 10.1007/s00262-024-03920-1. PubMed PMID:39751910 PubMed Central PMC11699035.

Search PubMed

2024

  1. Kiviaho, A, Eerola, SK, Kallio, HML, Andersen, MK, Hoikka, M, Tiihonen, AM et al.. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15 (1):9949. doi: 10.1038/s41467-024-54364-1. PubMed PMID:39550375 PubMed Central PMC11569175.
  2. Governa, V, de Oliveira, KG, Bång-Rudenstam, A, Offer, S, Cerezo-Magaña, M, Li, J et al.. Protumoral lipid droplet-loaded macrophages are enriched in human glioblastoma and can be therapeutically targeted. Sci Transl Med. 2024;16 (771):eadk1168. doi: 10.1126/scitranslmed.adk1168. PubMed PMID:39475570 .
  3. Huhtala, L, Karabiyik, G, Rautajoki, KJ. Development and epigenetic regulation of Atypical teratoid/rhabdoid tumors in the context of cell-of-origin and halted cell differentiation. Neurooncol Adv. 2024;6 (1):vdae162. doi: 10.1093/noajnl/vdae162. PubMed PMID:39465218 PubMed Central PMC11502914.
  4. Nurminen, R, Afyounian, E, Paunu, N, Katainen, R, Isomäki, M, Nurminen, A et al.. Previously reported CCDC26 risk variant and novel germline variants in GALNT13, AR, and MYO10 associated with familial glioma in Finland. Sci Rep. 2024;14 (1):11562. doi: 10.1038/s41598-024-62296-5. PubMed PMID:38773237 PubMed Central PMC11109329.
  5. Pekkarinen, M, Nordfors, K, Uusi-Mäkelä, J, Kytölä, V, Hartewig, A, Huhtala, L et al.. Aberrant DNA methylation distorts developmental trajectories in atypical teratoid/rhabdoid tumors. Life Sci Alliance. 2024;7 (6):. doi: 10.26508/lsa.202302088. PubMed PMID:38499326 PubMed Central PMC10948937.
  6. Kivioja, T, Posti, JP, Sipilä, J, Rauhala, M, Frantzén, J, Gardberg, M et al.. Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms. Front Oncol. 2023;13 :1305725. doi: 10.3389/fonc.2023.1305725. PubMed PMID:38239655 PubMed Central PMC10794640.

Search PubMed

2023
  1. Kivioja, T, Posti, JP, Sipilä, J, Rauhala, M, Frantzén, J, Gardberg, M et al.. Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms. Front Oncol. 2023;13 :1305725. doi: 10.3389/fonc.2023.1305725. PubMed PMID:38239655 PubMed Central PMC10794640.
  2. Lin, J, Moradi, E, Salenius, K, Lehtipuro, S, Häkkinen, T, Laiho, JE et al.. Distinct transcriptomic profiles in children prior to the appearance of type 1 diabetes-linked islet autoantibodies and following enterovirus infection. Nat Commun. 2023;14 (1):7630. doi: 10.1038/s41467-023-42763-9. PubMed PMID:37993433PubMed Central PMC10665402.
  3. Rautajoki, KJ, Jaatinen, S, Hartewig, A, Tiihonen, AM, Annala, M, Salonen, I et al.. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. Acta Neuropathol Commun. 2023;11 (1):176. doi: 10.1186/s40478-023-01669-9. PubMed PMID:37932833 PubMed Central PMC10629206.
  4. Alanen, E, Heikkinen, S, Nurminen, R, Nykter, M, Haapasalo, H, Hirvonen, E et al.. Early-onset grade 2-3 diffuse gliomas and schwannomas increase the risk of central nervous system tumors among the patients’ relatives. Neurooncol Adv. 2023;5 (1):vdad008. doi: 10.1093/noajnl/vdad008. PubMed PMID:36950216 PubMed Central PMC10025807.

Search PubMed

2022
  1. Rautajoki, KJ, Jaatinen, S, Tiihonen, AM, Annala, M, Vuorinen, EM, Kivinen, A et al.. PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. Sci Rep. 2022;12 (1):14083. doi: 10.1038/s41598-022-14977-2. PubMed PMID:35982066 PubMed Central PMC9388569.

Search PubMed

2021
  1. Taavitsainen, S, Engedal, N, Cao, S, Handle, F, Erickson, A, Prekovic, S et al.. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun. 2021;12 (1):5307. doi: 10.1038/s41467-021-25624-1. PubMed PMID:34489465 PubMed Central PMC8421417.
  2. Kukkonen, K, Taavitsainen, S, Huhtala, L, Uusi-Makela, J, Granberg, KJ, Nykter, M et al.. Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response. Cancers (Basel). 2021;13 (13):. doi: 10.3390/cancers13133325. PubMed PMID:34283056 PubMed Central PMC8268970.
  3. Filppu, P, Tanjore Ramanathan, J, Granberg, KJ, Gucciardo, E, Haapasalo, H, Lehti, K et al.. CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity. JCI Insight. 2021;6 (9):. doi: 10.1172/jci.insight.141486. PubMed PMID:33986188 PubMed Central PMC8262342.
  4. Rajamäki, K, Taira, A, Katainen, R, Välimäki, N, Kuosmanen, A, Plaketti, RM et al.. Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer. Gastroenterology. 2021;161 (2):592-607. doi: 10.1053/j.gastro.2021.04.042. PubMed PMID:33930428 .

Search PubMed

2020
  1. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):424-428. doi: 10.1016/j.ccell.2020.08.019. PubMed PMID:32931743 .
  2. Yang, M, Petralia, F, Li, Z, Li, H, Ma, W, Song, X et al.. Community Assessment of the Predictability of Cancer Protein and Phosphoprotein Levels from Genomics and Transcriptomics. Cell Syst. 2020;11 (2):186-195.e9. doi: 10.1016/j.cels.2020.06.013. PubMed PMID:32710834 .
  3. Dufva, O, Pölönen, P, Brück, O, Keränen, MAI, Klievink, J, Mehtonen, J et al.. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38 (3):380-399.e13. doi: 10.1016/j.ccell.2020.06.002. PubMed PMID:32649887 .
  4. Doan, P, Musa, A, Murugesan, A, Sipilä, V, Candeias, NR, Emmert-Streib, F et al.. Glioblastoma Multiforme Stem Cell Cycle Arrest by Alkylaminophenol Through the Modulation of EGFR and CSC Signaling Pathways. Cells. 2020;9 (3):. doi: 10.3390/cells9030681. PubMed PMID:32164385 PubMed Central PMC7140667.
  5. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .

Search PubMed

2019
  1. Granberg, KJ, Raita, A, Lehtinen, B, Tiihonen, AM, Kesseli, J, Annala, M et al.. Moderate-to-strong expression of FGFR3 and TP53 alterations in a subpopulation of choroid plexus tumors. Histol Histopathol. 2020;35 (7):673-680. doi: 10.14670/HH-18-180. PubMed PMID:31660579 .
  2. Pölönen, P, Mehtonen, J, Lin, J, Liuksiala, T, Häyrynen, S, Teppo, S et al.. Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Res. 2019;79 (10):2466-2479. doi: 10.1158/0008-5472.CAN-18-2970. PubMed PMID:30940663 .
  3. Lehtipuro, S, Nykter, M, Granberg, KJ. Modes of immunosuppression in glioblastoma microenvironment. Oncotarget. 2019;10 (9):920-921. doi: 10.18632/oncotarget.26643. PubMed PMID:30847018 PubMed Central PMC6398170.

Search PubMed

2018
  1. Luoto, S, Hermelo, I, Vuorinen, EM, Hannus, P, Kesseli, J, Nykter, M et al.. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma. Cancer Res. 2018;78 (19):5574-5585. doi: 10.1158/0008-5472.CAN-17-3714. PubMed PMID:29921698 .
  2. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Erratum: Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4 (3):. doi: 10.1101/mcs.a003129. PubMed PMID:29858379 PubMed Central PMC5983177.
  3. Nordfors, K, Haapasalo, J, Afyounian, E, Tuominen, J, Annala, M, Häyrynen, S et al.. Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. Cold Spring Harb Mol Case Stud. 2018;4 (2):. doi: 10.1101/mcs.a002246. PubMed PMID:29602769 PubMed Central PMC5880256.
  4. Haapasalo, J, Nordfors, K, Granberg, KJ, Kivioja, T, Nykter, M, Haapasalo, H et al.. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas. Histol Histopathol. 2018;33 (8):791-801. doi: 10.14670/HH-11-973. PubMed PMID:29441509 .

Search PubMed

2017
  1. Lehtinen, B, Raita, A, Kesseli, J, Annala, M, Nordfors, K, Yli-Harja, O et al.. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer. 2017;17 (1):310. doi: 10.1186/s12885-017-3274-9. PubMed PMID:28468611 PubMed Central PMC5415775.
  2. Granberg, KJ, Annala, M, Lehtinen, B, Kesseli, J, Haapasalo, J, Ruusuvuori, P et al.. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Neuro Oncol. 2017;19 (9):1206-1216. doi: 10.1093/neuonc/nox028. PubMed PMID:28379477 PubMed Central PMC5570261.

Search PubMed